High Tower Advisors, LLC Editas Medicine, Inc. Transaction History

High Tower Advisors, LLC

$68.3 Billion
Q3 2024

A detailed history of High Tower Advisors, LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 13,345 shares of EDIT stock, worth $17,481. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,345

Previous 16,228 17.77%

Holding current value

$17,481

Previous $75,000 40.0%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.39 - $5.96 $9,773 - $17,182	-2,883 Reduced 17.77%	13,345 $45,000
Q2 2024 Aug 13, 2024	BUY	$4.67 - $7.28 $3,782 - $5,896	810 Added 5.25%	16,228 $75,000
Q1 2024 May 06, 2024	SELL	$7.03 - $11.07 $10,383 - $16,350	-1,477 Reduced 8.74%	15,418 $114,000
Q4 2023 Feb 12, 2024	SELL	$6.25 - $11.11 $24,387 - $43,351	-3,902 Reduced 18.76%	16,895 $171,000
Q3 2023 Nov 08, 2023	SELL	$6.92 - $9.31 $7,881 - $10,604	-1,139 Reduced 5.19%	20,797 $162,000
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $27,933 - $50,376	4,392 Added 25.03%	21,936 $180,000
Q1 2023 May 11, 2023	SELL	$7.03 - $11.53 $703 - $1,153	-100 Reduced 0.57%	17,544 $127,000
Q4 2022 Feb 08, 2023	BUY	$8.32 - $13.21 $27,480 - $43,632	3,303 Added 23.03%	17,644 $156,000
Q3 2022 Nov 09, 2022	BUY	$12.16 - $19.42 $174,386 - $278,502	14,341 New	14,341 $174,000
Q1 2022 May 12, 2022	SELL	$14.08 - $27.63 $151,810 - $297,906	-10,782 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$26.55 - $40.57 $643,837 - $983,822	-24,250 Reduced 69.22%	10,782 $284,000
Q3 2021 Nov 12, 2021	SELL	$39.27 - $72.94 $916,169 - $1.7 Million	-23,330 Reduced 39.97%	35,032 $1.44 Million
Q2 2021 Aug 06, 2021	BUY	$31.29 - $56.64 $761,755 - $1.38 Million	24,345 Added 71.57%	58,362 $3.31 Million
Q1 2021 May 10, 2021	BUY	$39.71 - $90.58 $367,079 - $837,321	9,244 Added 37.31%	34,017 $1.43 Million
Q4 2020 Feb 10, 2021	SELL	$27.07 - $84.35 $15,213 - $47,404	-562 Reduced 2.22%	24,773 $1.73 Million
Q3 2020 Nov 13, 2020	BUY	$28.06 - $37.16 $218,026 - $288,733	7,770 Added 44.24%	25,335 $714,000
Q2 2020 Aug 10, 2020	BUY	$18.5 - $34.34 $120,805 - $224,240	6,530 Added 59.18%	17,565 $524,000
Q1 2020 May 21, 2020	BUY	$14.88 - $32.78 $164,200 - $361,727	11,035 New	11,035 $215,000
Q3 2019 Nov 12, 2019	SELL	$22.49 - $26.81 $418,741 - $499,175	-18,619 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$20.48 - $27.76 $28,098 - $38,086	1,372 Added 7.96%	18,619 $462,000
Q1 2019 May 15, 2019	BUY	$19.43 - $26.41 $335,109 - $455,493	17,247 New	17,247 $423,000
Q4 2018 Feb 14, 2019	SELL	$18.19 - $31.79 $125,074 - $218,588	-6,876 Closed	0 $0
Q3 2018 Nov 09, 2018	BUY	$27.65 - $38.39 $190,121 - $263,969	6,876 New	6,876 $219,000

Others Institutions Holding EDIT

# of Institutions

248

Shares Held

57M

Call Options Held

410K

Put Options Held

394K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.

Account

High Tower Advisors, LLC Editas Medicine, Inc. Transaction History